Daxor submits next-gen BVA to FDA for 510(k)/CLIA-waiver; clearance expected H1 2024

DAXOR CORP

Submission via dual 510(k)/CLIA-waiver pathway to FDA for next-generation blood volume analyzer.
New device designed to be three times faster, simpler, portable, and capable of bedside analysis.
Development funded under contract by U.S. Department of Defense.
Potential FDA clearance is expected during the first half of 2024.
Current BVA-100 is only FDA-cleared diagnostic for direct blood volume measurement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.